Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Senolytics in Previously Treated Glioma With Residual Disease
NCT07025226Phase 1Recruiting
- Sponsor
- Mayo Clinic
- Start
- Aug 2025
- Primary completion
- Sep 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of dasatinib, quercetin, fisetin and LMP744 in glioma (9 arms), sponsored by Mayo Clinic. Primary endpoints: Completion of 3 cycles at 16 weeks and Turnaround time for scan and marker data at 16 weeks. Started Aug 2025; status: recruiting.
02
Drugs
dasatinibquercetinfisetinLMP744
03
Conditions
glioma
Beyond the preview
Go deeper on NCT07025226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07025226.